INBX
Inhibrx Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$121.17
−0.89%Next report
Analyst consensus
- Next report date
- Nov 13, 2026
- EPS estimate
- -$2.45
- Revenue estimate
- $1.9M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$2.34
- EPS estimate
- -$2.28
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -1.1%
- Revenue beats (12Q)
- 2
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 13, 2026